Literature DB >> 2468716

Studies of sublines selected for loss of HLA expression from an EBV-transformed lymphoblastoid cell line. Changes in sensitivity to cytotoxic T cells activated by allostimulation and natural killer cells activated by IFN or IL-2.

C Ohlén1, M T Bejarano, A Grönberg, S Torsteinsdottir, L Franksson, H G Ljunggren, E Klein, G Klein, K Kärre.   

Abstract

Murine tumor studies have suggested that variations in MHC class I expression may influence the behavior of tumor cells in vivo. Corresponding human tumor studies remain at the descriptive level but they show differences in MHC Ag expression between and even within tumors. Our purpose was to explore possible functional relationships between class I expression and sensitivity to different forms of cell-mediated lysis in a potentially immunogenic system: EBV-immortalized B cells. Their cytotoxic sensitivity was tested to CTL and to IFN- or IL-2-activated effector cells. The wild-type line (high class I) was sensitive to CTL with the appropriate Ag restriction, but resisted lysis by normal or IFN-activated PBL. In contrast, HLA loss variants showed a reduced sensitivity to CTL and an increased NK sensitivity. The latter could be related to the loss of class I molecules: an intermediate (haplotype loss) expressor variant was moderately NK sensitive, whereas a weak expressor line, with an additional down-regulation of the remaining haplotype, was highly sensitive. IL-2-activated PBL ("LAK") cells showed the same killing pattern as NK cells, although the levels of lysis were generally higher. These data support the hypothesis that the MHC class I Ag expression-dependent, CTL-mediated lysis is complemented by additional mechanisms, mediated by effectors that recognize cells with reduced MHC Ag expression that would otherwise escape CTL-mediated rejection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2468716

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Histocompatibility antigens and natural killer susceptibility.

Authors:  J Peña; R Solana
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

Review 2.  Role of major histocompatibility complex class-I molecules in tumor rejection. New insights from studies with synthetic peptides and transgenic mice.

Authors:  P Höglund; H G Ljunggren; K Kärre; G Jay
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

3.  Search for the critical characteristics of phenotypically different B cell lines, Burkitt lymphoma cells and lymphoblastoid cell lines, which determine differences in their functional interaction with allogeneic lymphocytes.

Authors:  J Avila-Cariño; S Torsteinsdottir; B Ehlin-Henriksson; M G Masucci; E Klein
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.

Authors:  V Vĕtvicka; M Hanikýrová; J Vĕtvicková; G D Ross
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

Review 5.  Modulation of major histocompatibility complex antigen expression by viral infection.

Authors:  C R Rinaldo
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

6.  Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene.

Authors:  M Maio; M Altomonte; R Tatake; R A Zeff; S Ferrone
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

7.  Driving adenovirus type 12-transformed BALB/c mouse cells to express high levels of class I major histocompatibility complex proteins enhances, rather than abrogates, their tumorigenicity.

Authors:  S Soddu; A M Lewis
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

8.  Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes.

Authors:  N M Valiante; G Trinchieri
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307

9.  Regulation of hematopoiesis in vitro by alloreactive natural killer cell clones.

Authors:  G Bellone; N M Valiante; O Viale; E Ciccone; L Moretta; G Trinchieri
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.